Tech Transfer Roundup: How To Protect Downstream Rights
Executive Summary
A review of tech transfer deals over 10 years shows that licensees often protect their value positions to limit royalties paid out to licensors. Meanwhile, licensors often protect their future rights with language recognizing that additional parties may be involved in producing a final product.
You may also be interested in...
BlackThorn Raises $76m To Personalize Medicines For Neurobehavioral Disorders
BlackThorn's series B round will fund the use of AI and machine learning via its PathFinder platform and academic collaborations for the development of targeted therapies.
Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture
Private Company Edition: Westlake Village BioPartners launched with $320m and Harper as a managing director; UK-based Ahren unveiled a $100m-plus "deep science" fund; and UCSD partnered with Deerfield to finance drug programs. In new financings, Allogene leads with $120m.
Lexicon’s Sotagliflozin Succeeds In Heart Failure Following Disappointment In Diabetes
Lexicon gets broad indication across heart failure for its dual SGLT1/2 inhibitor, which will be positioned against Lilly/BI’s Jardiance and AstraZeneca’s Farxiga.